Regulation of human eosinophil serine protease 1- like enzyme

Abstract

A human eosinophil serine protease 1-like enzyme, cDNA, and reagents that regulate the enzyme can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, asthma, COPD, airway allergy, and osteoporosis.

1 . A cDNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof.  
     
     
         2 . The cDNA of  claim 1  which comprises the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         3 . The cDNA of  claim 1  which consists of the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         4 . An expression vector comprising a polynucleotide which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof.  
     
     
         5 . The expression vector of  claim 4  wherein the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         6 . The expression vector of  claim 4  wherein the polynucleotide consists of the nucleotide sequence shown in SEQ ID NO:1.  
     
     
         7 . A host cell comprising an expression vector which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof.  
     
     
         8 . The host cell of  claim 7  wherein the polynucleotide comprises the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         9 . The host cell of  claim 7  wherein the polynucleotide consists of the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         10 . A purified polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof.  
     
     
         11 . The purified polypeptide of  claim 10  which comprises the amino acid sequence shown in SEQ ID NO:2.  
     
     
         12 . The purified polypeptide of  claim 10  which comprises the amino acid sequence shown in SEQ ID NO:56.  
     
     
         13 . The purified polypeptide of  claim 10  which comprises the amino acid sequence shown in SEQ ID NO:57.  
     
     
         14 . The purified polypeptide of  claim 10  which comprises the amino acid sequence shown in SEQ ID NO:58.  
     
     
         15 . A fusion protein comprising a polypeptide consisting of an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof.  
     
     
         16 . The fusion protein of  claim 15  wherein the polypeptide consists of the amino acid sequence shown in SEQ ID NO:2.  
     
     
         17 . A method of producing a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof, comprising the steps of: 
 culturing a host cell comprising an expression vector that encodes the polypeptide under conditions whereby the polypeptide is expressed; and    isolating the polypeptide.    
     
     
         18 . The method of  claim 17  wherein the expression vector comprises the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         19 . A method of detecting a coding sequence for a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof, comprising the steps of: 
 hybridizing a polynucleotide comprising 11 contiguous nucleotides selected from the group consisting of (a) the complement of the nucleotide sequence shown in SEQ ID NO:1, (b) a polynucleotide that hybridizes under stringent conditions to (a), (c) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a) and (c) due to the degeneration of the genetic code, and (d) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a) to (c) to nucleic acid material of a biological sample to form a hybridization complex; and    detecting the hybridization complex.    
     
     
         20 . The method of  claim 19  further comprising the step of amplifying the nucleic acid material before the step of hybridizing.  
     
     
         21 . A kit for detecting a coding sequence for a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof, comprising: 
 a polynucleotide comprising 11 contiguous nucleotides selected from the group consisting of (a) the complement of the nucleotide sequence shown in SEQ ID NO:1, (b) a polynucleotide that hybridizes under stringent conditions to (a), (c) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a) and (c) due to the degeneration of the genetic code, and (d) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a) to (c); and    instructions for the method of  claim 19 .    
     
     
         22 . A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof, comprising the steps of: 
 contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and    detecting the reagent-polypeptide complex.    
     
     
         23 . The method of  claim 22  wherein the reagent is an antibody.  
     
     
         24 . A kit for detecting a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof, comprising: 
 an antibody which specifically binds to the polypeptide; and    instructions for the method of  claim 22 .    
     
     
         25 . A method of screening for agents that can regulate an activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of: 
 contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof; and    detecting binding of the test compound to the polypeptide, wherein a test compound that binds to the polypeptide is identified as a potential agent for regulating the activity of the human eosinophil serine protease 1-like enzyme.    
     
     
         26 . The method of  claim 25  wherein the step of contacting is in a cell.  
     
     
         27 . The method of  claim 26  wherein the cell is in vitro.  
     
     
         28 . The method of  claim 26  wherein the cell is in vivo.  
     
     
         29 . The method of  claim 25  wherein the step of contacting is in a cell-free system.  
     
     
         30 . The method of  claim 25  wherein the polypeptide comprises a detectable label.  
     
     
         31 . The method of  claim 25  wherein the test compound comprises a detectable label.  
     
     
         32 . The method of  claim 25  wherein the polypeptide is bound to a solid support.  
     
     
         33 . The method of  claim 25  wherein the test compound is bound to a solid support.  
     
     
         34 . A method of screening for therapeutic agents that can regulate an enzymatic activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of: 
 contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof; and    detecting the enzymatic activity of the polypeptide, wherein a test compound that increases the enzymatic activity of the polypeptide is identified as a potential therapeutic agent for increasing the enzymatic activity of the human eosinophil serine protease 1-like enzyme, and wherein a test compound that decreases the enzymatic activity of the polypeptide is identified as a potential therapeutic agent for decreasing the enzymatic activity of the human eosinophil serine protease 1-like enzyme.    
     
     
         35 . The method of  claim 34  wherein the step of contacting is in a cell.  
     
     
         36 . The method of  claim 35  wherein the cell is in vitro.  
     
     
         37 . The method of  claim 35  wherein the cell is in vivo.  
     
     
         38 . The method of  claim 34  wherein the step of contacting is in a cell-free system.  
     
     
         39 . A method of screening for therapeutic agents that can regulate an activity of a human eosinophil serine protease 1-like enzyme, comprising the steps of: 
 contacting a test compound with a product encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof; and    detecting binding of the test compound to the product, wherein a test compound that binds to the product is identified as a potential therapeutic agent for regulating the activity of the human eosinophil serine protease 1-like enzyme.    
     
     
         40 . The method of  claim 39  wherein the product is a polypeptide.  
     
     
         41 . The method of  claim 39  wherein the product is an RNA.  
     
     
         42 . A method of reducing an activity of a human eosinophil serine protease 1-like enzyme, comprising the step of: 
 contacting a cell comprising the human eosinophil serine protease 1-like enzyme with a reagent that specifically binds to a product encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof, whereby the activity of the human eosinophil serine protease 1-like enzyme is reduced.    
     
     
         43 . The method of  claim 42  wherein the product is a polypeptide.  
     
     
         44 . The method of  claim 43  wherein the reagent is an antibody.  
     
     
         45 . The method of  claim 42  wherein the product is an RNA.  
     
     
         46 . The method of  claim 45  wherein the reagent is an antisense oligonucleotide.  
     
     
         47 . The method of  claim 45  wherein the reagent is a ribozyme.  
     
     
         48 . The method of  claim 42  wherein the cell is in vitro.  
     
     
         49 . The method of  claim 42  wherein the cell is in vivo.  
     
     
         50 . A pharmaceutical composition, comprising: 
 a reagent that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2 and (b) biologically active variants thereof; and    a pharmaceutically acceptable carrier.    
     
     
         51 . The pharmaceutical composition of  claim 50  wherein the reagent is an antibody.  
     
     
         52 . A pharmaceutical composition, comprising: 
 a reagent that specifically binds to a product of a polynucleotide comprising a coding sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof; and    a pharmaceutically acceptable carrier.    
     
     
         53 . The pharmaceutical composition of  claim 52  wherein the reagent is a ribozyme.  
     
     
         54 . The pharmaceutical composition of  claim 52  wherein the reagent is an antisense oligonucleotide.  
     
     
         55 . The pharmaceutical composition of  claim 52  wherein the reagent is an antibody.  
     
     
         56 . A pharmaceutical composition, comprising: 
 an expression vector encoding a polypeptide comprising an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof; and    a pharmaceutically acceptable carrier.    
     
     
         57 . The pharmaceutical composition of  claim 56  wherein the expression vector comprises the nucleotide sequence shown in SEQ ID NO: 1.  
     
     
         58 . A method of treating a disorder selected from the group consisting of asthma, COPD, airway allergy, and osteoporosis, comprising the step of: 
 administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human eosinophil serine protease 1-like enzyme, wherein the human eosinophil serine protease 1-like enzyme comprises an amino acid sequence selected from the group consisting of (a) the amino acid sequences shown in SEQ ID NOS:2, 56, 57, and 58 and (b) biologically active variants thereof, whereby symptoms of the disorder are ameliorated.    
     
     
         59 . The method of  claim 58  wherein the reagent is identified by the method of  claim 25 .  
     
     
         60 . The method of  claim 58  wherein the reagent is identified by the method of  claim 34 .  
     
     
         61 . The method of  claim 58  wherein the reagent is identified by the method of  claim 39 .  
     
     
         62 . An isolated polynucleotide selected from the group consisting of: (a) a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO:2, 56, 57, or 58, (b) a polynucleotide comprising the sequence of SEQ ID NO: 1, (c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) or (b); (d) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a)-(c) due to the degeneration of the genetic code, and (e) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a)-(d).  
     
     
         63 . An expression vector comprising the polynucleotide of  claim 62 .  
     
     
         64 . A host cell comprising the expression vector of  claim 63 .  
     
     
         65 . A preparation of antibodies that specifically bind to a polypeptide selected from the group consisting of (a) the amino acid sequence shown in SEQ ID NO:2, 56, 57, or 58 and (b) biologically active variants thereof.  
     
     
         66 . An antisense oligonucleotide that hybridizes to a polynucleotide selected from the group consisting of (a) a polynucleotide encoding a protein that comprises the amino acid sequence of SEQ ID NO:2, 56, 57, or 58, (b) a polynucleotide comprising the sequence of SEQ ID NO:1, (c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) or (b), (d) a polynucleotide having a nucleic acid sequence that deviates from the nucleic acid sequences specified in (a)-(c) due to the degeneration of the genetic code, and (e) a polynucleotide that represents a fragment, derivative, or allelic variation of a nucleic acid sequence specified in (a)-(d).